Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Dengue Virus Polymerase Inhibitor (Balapiravir) in Male Patients With Confirmed Dengue Virus Infection.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Balapiravir (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Roche
- 19 Sep 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2011 Planned initiation date changed from 1 May 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.